Results of dienogest treatment and its discontinuation in patients with symptomatic adenomyosis: a prospective cohort study
Reproductive BioMedicine Online · 2025
DOI: 10.1016/j.rbmo.2025.104880 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Reproductive BioMedicine Online, 2025. Verfasst von Minhong Shen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Shanghai Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China. Hauptthemen laut MEDLINE: Nandrolone, Adenomyosis, Hormone Antagonists. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Shanghai Shen Kang Hospital Development Center, Shanghai Shenkang Hospital Development Center, National Natural Science Foundation of China.
Abstract (Originalsprache)
RESEARCH QUESTION: Do any factors in patients with symptomatic adenomyosis contribute to the greater alleviation of dysmenorrhoea and heavy menstrual bleeding (HMB) after treatment with dienogest, and what are the risk factors, if any, for recurrence if the dienogest treatment is discontinued? DESIGN: One hundred and twenty-five premenopausal patients diagnosed with adenomyosis by transvaginal ultrasound (TVUS), magnetic resonance imaging, or both. All patients underwent an ultrasound elastographic (TVESG) examination, and lesional stiffness was measured. All patients took dienogest (either branded or generic) for 6 months and were then instructed to stop for 3 months. Every 3 months after the start of treatment until 3 months after stopping, TVUS and TVESG examinations and symptoms were evaluated. Uterine size, lesional stiffness and haemoglobin levels were also measured. RESULTS: Treatment with dienogest resulted in symptom relief. Patients with more severe dysmenorrhoea or co-existing endometrioma had greater improvement in dysmenorrhoea (both P ≤ 0.042), but those with diffuse adenomyosis and co-existing fibroids responded less well. Discontinuation of the treatment causes relapse in some patients, and more severe symptoms and higher lesional stiffness were identified as factors for symptom recurrence (both P ≤ 0.017). CONCLUSIONS: Patients with adenomyosis with more severe dysmenorrhoea and HMB may benefit most from dienogest treatment, but also face higher recurrence risk if the treatment is discontinued, especially when their lesions are highly fibrotic. Therefore, only patients with severe dysmenorrhoea, severe HMB and higher lesional stiffness may require long-term medication, whereas others may take a break from daily medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, Shanghai Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China.
- Department of Gynecology, Shanghai Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Fudan University, Shanghai, Chi…
- Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Fudan University, Shanghai, China; Research Institute, Shanghai Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China. El…
Förderung
- Shanghai Shen Kang Hospital Development Center
- Shanghai Shenkang Hospital Development Center
- National Natural Science Foundation of China
Zitieren
APA
Shen, M., Liu, X., Ding, D., & Guo, S. W. (2025). Results of dienogest treatment and its discontinuation in patients with symptomatic adenomyosis: a prospective cohort study. Reproductive BioMedicine Online. https://doi.org/10.1016/j.rbmo.2025.104880
Vancouver
Shen M, Liu X, Ding D, Guo SW. Results of dienogest treatment and its discontinuation in patients with symptomatic adenomyosis: a prospective cohort study. Reproductive BioMedicine Online. 2025. doi:10.1016/j.rbmo.2025.104880
BibTeX
@article{Shen2025,
author = {Shen, Minhong and Liu, Xishi and Ding, Ding and Guo, Sun-Wei},
title = {Results of dienogest treatment and its discontinuation in patients with symptomatic adenomyosis: a prospective cohort study},
journal = {Reproductive BioMedicine Online},
year = {2025},
doi = {10.1016/j.rbmo.2025.104880}
}
EUVIMED